RxDoctor Payments Data

Neeraj Dubey, MD

Neurology · Philadelphia, PANPI 1215980818

Payments from drug & device makers

$153,069in general payments, 2019–2025

Across 519 payments — averaging $294.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$101K
  • Eisai Inc.$43K
  • EMD Serono, Inc.$1K
  • Abbott$1K
  • Livanova USA, Inc.$750
  • Medtronic$501
  • plus $5K from 46 others

What the payments were for

  • Consulting fees$5,4554%
  • Speaking & faculty fees$125,57982%
  • Travel & lodging$9,5056%
  • Food & beverage$12,3508%
  • Education$1810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,069 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$103,054
Medicare patients
414
Services billed
5,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$128,168
VumerityDiroximel Fumarate12$104,056
NuplazidPimavanserin Tartrate13$85,804
RytaryCarbidopa/Levodopa78$55,578
Nurtec OdtRimegepant Sulfate19$37,645
XcopriCenobamate28$31,225
FycompaPerampanel15$25,969
UbrelvyUbrogepant16$25,398
AptiomEslicarbazepine Acetate18$21,489
Aimovig AutoinjectorErenumab-Aooe19$20,083
NamzaricMemantine Hcl/Donepezil Hcl12$10,161
Memantine Hcl269$9,824
Rivastigmine30$5,640
Gabapentin284$4,842
Lacosamide18$4,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$91$128,16819 claims
BiogenVumerity$94$104,05612 claims
Acadia Pharmaceuticals IncNuplazid$108$85,80413 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$218$56,85397 claims
PfizerNurtec Odt$94$37,64519 claims
AbbVieUbrelvy, Namzaric$100,939$35,55828 claims
SK Life Science, Inc.Xcopri$218$31,22528 claims
Eisai Inc.Fycompa$43,363$25,96915 claims
Sunovion Pharmaceuticals Inc.Aptiom$66$21,48918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →